Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FGFR3 rearrange |
| Therapy | Fexagratinib |
| Indication/Tumor Type | myeloid neoplasm |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR3 rearrange | myeloid neoplasm | sensitive | Fexagratinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Fexagratinib (AZD4547) inhibited survival of myeloma cells harboring FGFR3 translocation in culture and in cell line xenograft models (PMID: 27550940). | 27550940 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (27550940) | Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547. | Full reference... |